Baricitinib/propofolPancreatitis following off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1903卷 / 1期

关键词：

D O I：

10.1007/s40278-022-13649-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：87 / 87

相关论文

共 50 条

[21] DaratumumabHypogammaglobulinemia following off-label use: case report
Reactions Weekly, 2019, 1744 (1) : 111 - 111
[22] NivolumabPsoriasis following an off-label use: case report
Reactions Weekly, 2018, 1717 (1) : 214 - 214
[23] GlibenclamideHypoglycaemia following off-label use: case report
Reactions Weekly, 2021, 1857 (1) : 162 - 162
[24] CatequentinibPneumothorax following off-label use: case report
Reactions Weekly, 2022, 1925 (1) : 158 - 158
[25] TolvaptanHypernatraemia following off-label use: case report
Reactions Weekly, 2019, 1753 (1) : 326 - 326
[26] FelbamateNeutropenia following off-label use: case report
Reactions Weekly, 2020, 1803 (1) : 111 - 111
[27] MethylprednisoloneFungaemia following an off-label use: case report
Reactions Weekly, 2022, 1899 (1) : 243 - 243
[28] SirolimusPneumonia following off-label use: case report
Reactions Weekly, 2020, 1800 (1) : 269 - 269
[29] ClonazepamMisidentification following off-label use: case report
Reactions Weekly, 2022, 1926 (1) : 171 - 171
[30] RituximabAgranulocytosis following off-label use: case report
Reactions Weekly, 2018, 1712 (1) : 482 - 482

← 1 2 3 4 5 →